Key points are not available for this paper at this time.
This study provides Class II evidence that in individuals with CKD stage 3 (especially stage 3b) or higher, p-tau217 concentrations are increased, with a greater increase in amyloid-PET-negative individuals.
Bornhorst et al. (Fri,) studied this question.